Boston Scientific (NYSE:BSX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at BTIG Research in a research report issued on Monday,Benzinga reports. They presently have a $80.00 price target on the medical equipment provider’s stock. BTIG Research’s price target points to a potential upside of 46.76% from the stock’s current price.
A number of other analysts have also commented on the company. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. TD Cowen dropped their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Stifel Nicolaus dropped their price target on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Finally, Mizuho cut their price objective on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $93.91.
Get Our Latest Stock Report on BSX
Boston Scientific Stock Up 3.5%
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s revenue was up 11.6% on a year-over-year basis. During the same period last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts forecast that Boston Scientific will post 3.38 EPS for the current fiscal year.
Institutional Investors Weigh In On Boston Scientific
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BSX. Vanguard Group Inc. boosted its stake in Boston Scientific by 0.8% during the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after buying an additional 1,115,337 shares during the last quarter. Rathbones Group PLC boosted its position in shares of Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after acquiring an additional 477,680 shares during the last quarter. Tounjian Advisory Partners LLC purchased a new position in shares of Boston Scientific in the fourth quarter valued at $1,477,000. Kepler Cheuvreux Suisse SA bought a new stake in Boston Scientific in the third quarter worth $26,955,000. Finally, Waycross Partners LLC purchased a new stake in Boston Scientific during the fourth quarter valued at $2,384,000. Institutional investors own 89.07% of the company’s stock.
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles
- Five stocks we like better than Boston Scientific
- Consumer-Driven Stocks Boost Buybacks, Including Visa’s $20B Plan
- Iran Ceasefire Trade: 3 Energy Stocks to Own if Oil Falls to $80
- Willing and Abel: Berkshire’s New CEO Makes Huge Portfolio Changes in Q1
- Insider Buying Says Upstart Isn’t Down for the Count
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
